About Calidi Biotherapeutics Inc
- Industry: Biotechnology
- Exchange: NYSE MKT LLC
- Country: US
- Website: https://www.calidibio.com/
Frequently Asked Questions
What is the 52-week range for CLDI?
The 52-week high is $27.84 and the 52-week low is $1.03.
What is the P/E ratio for CLDI?
The P/E ratio data is currently unavailable.
What is the dividend yield for CLDI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -372.85%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.23.
Analyst Recommendation Trends
Wall Street analyst consensus for CLDI over the last few months:
Latest CLDI News
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the Company received a notice (the “Notice”) from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(ii)of the NYSE American C
Calidi Biotherapeutics Receives NYSE American Non-Compliance Notice
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company’s common stock, in a registered direct offering, at a per share purchase price o
Calidi Biotherapeutics Announces Registered Direct Offering 1,025,640 Shares At $1.17 Per Share
The closing of the registered direct offering is expected to occur on or about September 18, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Calidi from the registered direct
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Eric Poma, Ph.D., Chief Executive Officer of Calidi Biotherapeutics will hold one-on-one meetin
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-17 | Peoples George | +4,000 | - | - |
| 2026-08-17 | Leftwich Scott | +4,000 | - | - |
| 2026-08-17 | Fernandez Santidrian Antonio | +16,000 | - | - |
| 2026-08-17 | Sanders Corazon (Corsee) D. | +6,000 | - | - |
| 2026-08-17 | Stewart Alan R. | +4,000 | - | - |
| 2026-08-17 | Jackson Andrew C. | +14,000 | - | - |
| 2026-08-17 | Schoeneck James A | +5,000 | - | - |
| 2026-08-17 | Poma Eric E | +32,000 | - | - |
| 2025-12-12 | Camaisa Allan | -850 | $1.455 | $1,237 |